New drug aims to boost brain energy in Parkinson's patients

NCT ID NCT07322887

Recruiting now Disease control Sponsor: GEN İlaç ve Sağlık Ürünleri A.Ş. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new drug called SUL-238 can improve energy production in brain cells of people with early, untreated Parkinson's disease. Forty-five participants will take either a low or high dose of SUL-238 or a placebo daily for 28 days. Researchers will use a special MRI scan to measure brain energy levels and check for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SUL-238
What this could lead to: If successful, this could point toward a new way to improve brain cell energy in early Parkinson's, potentially slowing disease progression.
What could go wrong: This is a small, early-phase trial with only 45 people over 28 days. It measures brain chemistry changes, not symptoms or long-term outcomes, so success is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PARKINSON'S DISEASE (PD)

Contacts and locations

Locations

CTC Netherlands BV
RECRUITING

Groningen, 9713 GZ, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.